Elevation Cash Per Share from 2010 to 2024

ELEV Stock  USD 0.60  0.01  1.64%   
Elevation Oncology Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share is likely to outpace its year average in 2024. During the period from 2010 to 2024, Elevation Oncology Cash Per Share regression line of quarterly data had mean square error of  2.13 and geometric mean of  0.27. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
2.43875206
Current Value
2.57
Quarterly Volatility
1.96066831
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 K, Interest Expense of 4.4 M or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.35. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
  
Check out the analysis of Elevation Oncology Correlation against competitors.
For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.

Latest Elevation Oncology's Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Elevation Oncology over the last few years. It is Elevation Oncology's Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elevation Oncology's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 5.26 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Elevation Cash Per Share Regression Statistics

Arithmetic Mean1.28
Geometric Mean0.27
Coefficient Of Variation152.65
Mean Deviation1.61
Median0.07
Standard Deviation1.96
Sample Variance3.84
Range6.2305
R-Value0.70
Mean Square Error2.13
R-Squared0.48
Significance0
Slope0.31
Total Sum of Squares53.82

Elevation Cash Per Share History

2024 2.57
2023 2.44
2022 3.88
2021 6.3
2020 3.34

About Elevation Oncology Financial Statements

Elevation Oncology investors use historical fundamental indicators, such as Elevation Oncology's Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 2.44  2.57 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.